learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
Search
forLearn
1 / 1 resultsResearch
5 / 1000+ results
research Toxicity Profile of Antibody-Drug Conjugates in Breast Cancer: Practical Considerations
ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.
research Targeting Integrin Pathways: Mechanisms and Advances in Therapy
New therapies are being developed that target integrin pathways to treat various diseases.
research Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Adding a second method to PROTACs could improve cancer treatment.
research Neoadjuvant Therapy With Disitamab Vedotin in Treating Muscle-Invasive Bladder Cancer: A Case Report
Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
research Trends in Nanotechnology for Practical Applications
Nanotechnology is improving drug delivery and targeting, with promising applications in cancer treatment, gene therapy, and cosmetics, but challenges remain in ensuring precise delivery and safety.
Community Join
5 / 38 resultscommunity Testosterone and hair loss seeming irrelevance
The conversation is about the role of testosterone in hair loss and the effectiveness of different treatments. The conclusion is that DHT is the main culprit for hair loss, and finasteride has been proven to work long-term in maintaining and regrowing hair. Testosterone may have a minor effect, but it is not the primary cause of hair loss.
community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
community HMI-115 question about potential earliest access
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.
community All Drugs in Clinical Trials in 2023
12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.
community Residents of Victoria, Australia, sign up for a monoclonal antibody clinical trial – potential cure
A monoclonal antibody clinical trial for potential hair loss treatments in Victoria, Australia and the discussion of their efficacy. People shared information about similar drugs already on the market, speculated about potential side effects, and discussed how to spread the word about the trial.